{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:16:43Z","timestamp":1762273003673},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:p>This Viewpoint discusses the use of hallucinogens to treat alcohol use disorder.<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2022.2029","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T15:32:17Z","timestamp":1661355137000},"page":"945","source":"Crossref","is-referenced-by-count":3,"title":["Treating Alcohol Use Disorder With Hallucinogens\u2014Renewed Interest After a 50-Year Hiatus"],"prefix":"10.1001","volume":"79","author":[{"given":"Henry R.","family":"Kranzler","sequence":"first","affiliation":[{"name":"Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine, Philadelphia"},{"name":"Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily E.","family":"Hartwell","sequence":"additional","affiliation":[{"name":"Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine, Philadelphia"},{"name":"Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"yed220003r1","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/acer.13093","article-title":"Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development.","volume":"40","author":"Litten","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"yed220003r2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review.","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"yed220003r3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ajad.2003.12.issue-4","article-title":"Barriers to the use of medications to treat alcoholism.","volume":"12","author":"Mark","year":"2003","journal-title":"Am J Addict"},{"key":"yed220003r4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/bs.apha.2021.10.003","article-title":"Human behavioral pharmacology of psychedelics.","volume":"93","author":"Strickland","year":"2022","journal-title":"Adv Pharmacol"},{"issue":"7","key":"yed220003r5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"yed220003r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder:a randomized clinical trial.","author":"Bogenschutz","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yed220003r7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin.","volume":"7","author":"Passie","year":"2002","journal-title":"Addict Biol"},{"key":"yed220003r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2022.2044096","article-title":"The use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile: a systematic review.","author":"Hodge","year":"2022"},{"issue":"2","key":"yed220003r9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.v143.2","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies.","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"yed220003r10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression.","volume":"28","author":"Daws","year":"2022","journal-title":"Nat Med"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2795627\/jamapsychiatry_kranzler_2022_ed_220003_1664208858.21018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T15:01:28Z","timestamp":1664982088000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2795627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2029","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}